Beta-propiolactone treatment impairs the biological activity of residual DNA from BHK-21 cells infected with rabies virus.

[1]  D. Schmid,et al.  The protective role of humoral neutralizing antibody in the NIH potency test for rabies vaccines. , 1991, Vaccine.

[2]  N. Tordo,et al.  PCR technique as an alternative method for diagnosis and molecular epidemiology of rabies virus. , 1991, Molecular and cellular probes.

[3]  P. Perrin,et al.  Appraisal of rabies vaccine potency by determination of in vitro, specific interleukin-2 production. , 1991, Biologicals : journal of the International Association of Biological Standardization.

[4]  P. Perrin,et al.  In vitro rabies vaccine potency appraisal by ELISA: advantages of the immunocapture method with a neutralizing anti-glycoprotein monoclonal antibody. , 1990, Biologicals : journal of the International Association of Biological Standardization.

[5]  D. Magrath,et al.  Status of WHO concerning continuous cell lines as substrates for the production of biologicals. , 1989, Developments in biological standardization.

[6]  B. Montagnon.  Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line. , 1989, Developments in biological standardization.

[7]  G. Peiwei,et al.  Experience with production of interferon and Japanese encephalitis vaccine in continuous cell lines. , 1989, Developments in biological standardization.

[8]  Regan Pj,et al.  The approach used to establish the safety of veterinary vaccines produced in the BHK 21 cell line. , 1987 .

[9]  Adams Gl,et al.  WHO Study Group on Biologicals: history, issues and goals of the meeting. , 1987 .

[10]  D. Pye,et al.  Inactivation of poliovirus with β-propiolactone , 1986 .

[11]  Petricciani Jc.  Safety issues relating to the use of mammalian cells as hosts. , 1985 .

[12]  P. Perrin,et al.  Étude de l'adsorption et de la pénétration du virus rabique: Interactions avec les cellules BHK21 et des membranes artificielles , 1982 .

[13]  J. Mieyal,et al.  The reaction of β-propiolactone with derivatives of adenine and with DNA , 1981 .

[14]  C. V. van Beveren,et al.  Detection and elimination of cellular nucleic acids in biologicals produced on continuous cell lines. , 1981, Developments in biological standardization.

[15]  J. Miller,et al.  Estimation of apurinic/apyrimidinic sites and phosphotriesters in deoxyribonucleic acid treated with electrophilic carcinogens and mutagens. , 1980, Biochemistry.

[16]  J. Solomon,et al.  Isolation of 3-(2-carboxyethyl)thymine following in vitro reaction of β-propiolactone with calf thymus DNA , 1980 .

[17]  D. Brusick,et al.  The genetic properties of beta-propiolactone. , 1977, Mutation research.

[18]  L. Loeb,et al.  Restriction of carcinogen-induced error incorporation during in vitro DNA synthesis. , 1976, Cancer research.

[19]  W. C. Nietert,et al.  DNA-Protein Complexes Produced by a Carcinogen, β-Propiolactone , 1974 .

[20]  B. L. Duuren,et al.  Studies of the effects in vitro of β-propiolactone and β-propiolact[14C]one on whole mouse skin chromatin☆ , 1974 .

[21]  R. Williamson.  Properties of rapidly labelled deoxyribonucleic acid fragments isolated from the cytoplasm of primary cultures of embryonic mouse liver cells. , 1970, Journal of molecular biology.

[22]  N. Colburn,et al.  IN VIVO REACTIONS OF β‐PROPIOLACTONE , 1969 .

[23]  H. Koprowski,et al.  Immunogenicity of Concentrated and Purified Rabies Vaccine of Tissue Culture Origin∗ , 1969, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[24]  N. Colburn,et al.  The in Vivo Binding of β-Propiolactone to Mouse Skin DNA, RNA, and Protein , 1968 .

[25]  I. Macpherson,et al.  Polyoma transformation of hamster cell clones--an investigation of genetic factors affecting cell competence. , 1962, Virology.

[26]  P. D. Lawley,et al.  The reaction of mono- and di-functional alkylating agents with nucleic acids. , 1961, The Biochemical journal.

[27]  G. Logrippo.  INVESTIGATIONS OF THE USE OF BETA‐PROPIOLACTONE IN VIRUS INACTIVATION * , 1960, Annals of the New York Academy of Sciences.

[28]  F. W. Hartman,et al.  Antigenicity of β-Propiolactone-Inactivated Virus Vaccines , 1955, The Journal of Immunology.